Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merav Leiba

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's MacroglobulinemiaRamón Garcia-Sanz, Marzia Varettoni, Cristina Jiménez, et al.
Ejhaem|July 18, 2022
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomibPaul G Richardson, Arnon Nagler, Dina Ben-Yehuda, et al.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
Hemasphere|November 15, 2019
Insights on Multiple Myeloma Treatment StrategiesMaría-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, et al.
Leukemia & Lymphoma|August 18, 2021
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcomeIlana Levy, Avital Lavi, Eran Zimran, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 1 from the 11<sup>th</sup> International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patientsChristian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's MacroglobulinemiaRamón Garcia-Sanz, Marzia Varettoni, Cristina Jiménez, et al.
Ejhaem|July 18, 2022
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomibPaul G Richardson, Arnon Nagler, Dina Ben-Yehuda, et al.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
Hemasphere|November 15, 2019
Insights on Multiple Myeloma Treatment StrategiesMaría-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, et al.
Leukemia & Lymphoma|August 18, 2021
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcomeIlana Levy, Avital Lavi, Eran Zimran, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 1 from the 11<sup>th</sup> International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patientsChristian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Pageof 7